Tumor microenvironment vasculature

The "tumor microenvironment vasculature" refers collectively to the abnormal network of blood vessels within the tumor microenvironment, distinguished from normal vasculature by highly disorganized architecture, leaky and tortuous vessels, and defective endothelial junctions[1][5][8][10]. These abnormalities result from dysregulated angiogenesis—primarily driven by signaling molecules such as VEGF and Angiopoietin 2—and contribute to key features of the tumor microenvironment including hypoxia, acidosis, increased interstitial fluid pressure, and impaired immune cell infiltration[3][4][5]. The vasculature within tumors is a major determinant of tumor growth, metastatic spread, therapeutic resistance, and immune evasion, but "tumor microenvironment vasculature" itself is not a single molecule or canonical drug target; rather, it is a structural/functional entity comprising various cellular and molecular components (e.g., endothelial cells, pericytes)[1][4][7]. Current pharmacological approaches target components or pathways of this vasculature, such as VEGFR or Tie2, aiming to inhibit or normalize angiogenesis for therapeutic benefit in cancer[2][3][5].

Other names

Tumor vasculatureTumor-associated vasculatureTumor blood vessels

Inhibition of VEGF/VEGFR signaling (blocking angiogenesis) Normalization of vascular structure/function Dual inhibition of Angiopoietin-Tie2 and VEGF pathways Vascular disruption Increased immune infiltration via vascular normalization